{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ta%2FT1", "query": { "condition": "Ta/T1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ta%2FT1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T11:45:59.114Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06390111", "title": "A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bladder Cancer", "Ta/T1", "CIS" ], "interventions": [ { "name": "nadofaragene firadenovec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2024-06-17", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 2, "location_summary": "Little Rock, Arkansas • Atlanta, Georgia", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06390111" }, { "nct_id": "NCT07322263", "title": "Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Non-Muscle Invasive Bladder Cancer (NMIBC)", "Urothelial Carcinoma", "Carcinoma in Situ (CIS)", "High-Grade Papillary Bladder Tumors", "BCG-Unresponsive Bladder Cancer", "Ta Stage Bladder Cancer", "T1 Stage Bladder Cancer", "BCG-Refractory Bladder Cancer", "High-Risk NMIBC", "Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)" ], "interventions": [ { "name": "Intravesical Gemcitabine and Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael A. O'Donnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 174, "start_date": "2026-04-10", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322263" }, { "nct_id": "NCT04109092", "title": "A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "E7766", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-02-13", "completion_date": "2022-09-29", "has_results": false, "last_update_posted_date": "2020-12-14", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 9, "location_summary": "Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 6 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04109092" }, { "nct_id": "NCT06026332", "title": "ADSTILADRIN Early Utilization and Outcomes in the Real World Setting", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "ADSTILADRIN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2023-09-15", "completion_date": "2026-01-15", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 31, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06026332" }, { "nct_id": "NCT03552796", "title": "sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Bladder Carcinoma", "Bladder Cancer Stage 0", "Bladder Cancer Stage I" ], "interventions": [ { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2023-08-01", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03552796" }, { "nct_id": "NCT00003725", "title": "Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "valrubicin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Anthra Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "1996-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003725" }, { "nct_id": "NCT04387461", "title": "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "CG0070", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab Injection", "type": "BIOLOGICAL" }, { "name": "n-dodecyl-B-D-maltoside", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "CG Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2020-12-08", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 13, "location_summary": "La Jolla, California • Orange, California • Tampa, Florida + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387461" }, { "nct_id": "NCT03258593", "title": "Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Vicineum", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Bladder Biopsy", "type": "PROCEDURE" }, { "name": "TURBT", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Urine cytology", "type": "DIAGNOSTIC_TEST" }, { "name": "Electrocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-06-07", "completion_date": "2022-10-17", "has_results": true, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03258593" }, { "nct_id": "NCT04452591", "title": "Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Muscle Invasive Bladder Cancer", "High-grade Ta/ T1 Papillary Disease Bladder Cancer" ], "interventions": [ { "name": "Cretostimogene Grenadenorepvec", "type": "BIOLOGICAL" }, { "name": "n-dodecyl-B-D-maltoside", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "CG Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2020-10-27", "completion_date": "2031-12-24", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 45, "location_summary": "Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04452591" }, { "nct_id": "NCT05024773", "title": "Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Carcinoma in Situ (CIS)" ], "interventions": [ { "name": "ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fidia Farmaceutici s.p.a.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2022-12-29", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-07T11:45:59.114Z", "location_count": 6, "location_summary": "Gilbert, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024773" } ] }